Article
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation.
Breast cancer research and treatment - 1 Sept 2023
Kotsopoulos Joanne, Gronwald Jacek, Huzarski Tomasz, Aeilts Amber, Randall Armel Susan, Karlan Beth, Singer Christian F, Eisen Andrea, Tung Nadine, Olopade Olufunmilayo, Bordeleau Louise, Eng Charis, Foulkes William D, Neuhausen Susan L, Cullinane Carey A, Pal Tuya, Fruscio Robert, Lubinski Jan, Metcalfe Kelly, Sun Ping, Narod Steven A
Abstract excerpt
PURPOSE: Chemoprevention with a selective estrogen receptor modulator (tamoxifen or raloxifene) is a non-surgical option offered to high-risk women to reduce the risk of breast cancer. The evidence for tamoxifen benefit is based on trials conducted among predominantly postmenopausal women from the general population and on studies of contralateral breast cancer in women with a pathogenic variant (mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.